Skip to main content
. 2009 Jun 1;27(21):3423–3429. doi: 10.1200/JCO.2008.17.2254

Fig 2.

Fig 2.

Kaplan-Meier estimate of disease-free survival (DFS) and disease-specific survival (DSS) in cohort 1, according to estrogen receptor (ER)-α36 expression. (A) DFS and (B) DSS in 307 ER-α66–positive patients who received tamoxifen treatment (chemotherapy plus tamoxifen or tamoxifen alone); (C) DFS or (D) DSS in 129 ER-α66–positive patients who did not receive tamoxifen therapy (chemotherapy alone); (E) DFS or (F) DSS in 73 ER-α66–negative patients who received tamoxifen therapy (chemotherapy plus tamoxifen or tamoxifen alone); (G) DFS or (H) DSS in 149 ER-α66–negative patients who did not receive tamoxifen therapy (chemotherapy alone).